Research programme - anti-cancer therapeutics - Gnubiotics sciences
Latest Information Update: 26 Jul 2022
At a glance
- Originator Gnubiotics Sciences
- Class Antineoplastics; Glycopeptides
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colorectal cancer; Skin cancer
Most Recent Events
- 06 Jul 2022 Gnubiotics Sciences collaborates with University Hospital Zurich for the development of the glycopeptides for the treatment of solid tumours
- 15 Oct 2021 Preclinical trials in Colorectal cancer in Switzerland (PO) (Gnubiotics pipeline, October 2021)
- 15 Oct 2021 Preclinical trials in Skin cancer in Switzerland (PO) (Gnubiotics pipeline, October 2021)